Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...
Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 ...
(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at ...
Carla Harris has been diagnosed with and beaten acute myeloid leukemia thanks to a bone marrow transplant from her sister, ...
A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...
Research showed links between smoking heavily and developing genetic mutations and a greater risk for myelodysplastic ...
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...
Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from ...
Study reveals how socioeconomic factors create barriers to bone marrow transplants for AML patients in disadvantaged ...
A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...